Neurimmune, a global leader in the discovery and development of human-derived monoclonal antibodies, today announced that the company is expanding its clinical development team in expectation of selected in-house therapeutic programs moving towards clinical trials. Neurimmune’s co-founder and Board Member Christoph Hock has been appointed in August 2018 to the newly created position of Chief Medical Officer (CMO) in order to lead clinical programs in the fields of neurodegeneration, cardiomyopathy and metabolic disorders.
“At Neurimmune, we are working hard to bring human-derived antibodies to the clinic in order to treat and prevent human diseases caused by pathological protein aggregates. The recently raised funding enables us to grow our company further and to establish a division for clinical development”, said Roger Nitsch, Neurimmune’s CEO & President. “We are pleased that Christoph joins Neurimmune to lead our clinical trial teams. He has an impressive track record in clinical research and academic leadership. Christoph will play a key role in advancing Neurimmune’s therapeutic candidates to clinical proof-of-concept.”
Christoph Hock is a board-certified psychiatrist and an internationally recognized key opinion leader on Alzheimer’s disease and related disorders. Christoph Hock previously served as Vice-President Medicine and Science on the executive board of the University of Zurich, and as a member of the Research Council of the Swiss National Science Foundation. In addition to his role at Neurimmune, he holds a part-time professorship of biological psychiatry at the Institute for Regenerative Medicine (IREM) of the University of Zurich.
Contact Neurimmune
Fabian Buller, PhD
CBO
fabian.buller@neurimmune.com
Neurimmune AG
